卡瑞利珠单抗是一种人源化的抗PD-1单克隆抗体.在体外与人和食蟹猴PD-1蛋白具有纳摩尔级别的高亲和力,但不结合鼠源PD-1蛋白.它在......

Camrelizumab,a programmed cell death 1(PD-1)inhibitor,has been approved for the treatment of patients with relapsed or r......

1例55岁男性患者,因肝癌晚期伴腹腔转移,术后口服仑伐替尼(12mg,qd),1个月后抗癌方案调整为仑伐替尼联合卡瑞利珠(200mg,q2w,ivgtt......

目的:观察卡瑞利珠单抗联合化疗一线治疗晚期/转移性非鳞状非小细胞肺癌(NSCLC)的疗效。方法:选取我院收治的88例晚期/转移性非鳞......

BACKGROUND Oncologic immunotherapy is attracting attention as an effective strategy for cancer treatment. Currently, the......